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AbstrACt
Objectives To determine whether data on research 
studies held by the UK Health Research Authority (HRA) 
could be summarised automatically with minimal manual 
intervention. There are numerous initiatives to reduce 
research waste by improving the design, conduct, analysis 
and reporting of clinical studies. However, quantitative data 
on the characteristics of clinical studies and the impact of 
the various initiatives are limited.
Design Feasibility study, using 1 year of data.
setting We worked with the HRA on a pilot study using 
research applications submitted for UK-wide ethical 
review. We extracted into a single dataset, information 
held in anonymised XML files by the Integrated Research 
Application System (IRAS) and the HRA Assessment 
Review Portal (HARP). Research applications from 2014 
to 2016 were provided. We used standard text extraction 
methods to assess information held in free-text fields. 
We use simple, descriptive methods to summarise the 
research activities that we extracted.
Participants Not applicable—records-based study
Interventions Not applicable.
Primary and secondary outcome measures Feasibility 
of extraction and processing.
results We successfully imported 1775 non-duplicate 
research applications from the XML files into a single 
database. Of these, 963 were randomised controlled trials 
and 812 were other studies. Most studies received a 
favourable opinion. There was limited patient and public 
involvement in the studies. Most, but not all, studies were 
planned for publication of results. Novel study designs 
(eg, adaptive and Bayesian designs) were infrequently 
reported.
Conclusions We have demonstrated that the data 
submitted from IRAS to the HRA and its HARP system 
are accessible and can be queried for information. We 
strongly encourage the development of fully resourced 
collaborative projects to further this work. This would aid 
understanding of how study characteristics change over 
time and across therapeutic areas, as well as the progress 
of initiatives to improve the quality and relevance of 
research studies.
IntrODuCtIOn 
The need to improve the quality of clinical 
research is increasingly understood.1 With 
a particular focus on clinical studies, the 
‘gold standard’ for evidence-based medicine, 
there has been a noticeable push towards: 
improving study protocols1; developing and 
implementing newer methodologies, such as 
adaptive designs2; involving patients in the 
design, conduct and management of studies3; 
and ensuring that study results are quickly 
and accurately reported.4 
In order to properly evaluate the current 
state of clinical research and changes over 
time, it is clearly necessary to have unfettered 
access to the research protocols and study 
results.5 6 There are a number of limitations 
in accessing such information. Published 
evaluations of the state of clinical research 
are mainly based on the clinical study publi-
cation due to the difficulty in obtaining 
access to unpublished research protocols.7 
Research registers are incomplete for many 
jurisdictions and/or are, like study publica-
tions, limited in detail compared with the 
research protocol. For example,  clinicaltrials. 
gov8 has good coverage of clinical studies in 
North America, where registration of clinical 
trials is mandatory. The WHO International 
strengths and limitations of this study
 ► First study to draw information from Health Research 
Authority (HRA’s) Assessment Review Portal HARP 
system into one searchable dataset.
 ► Anonymised data from the HRA’s HARP system can 
be interrogated with minimal manual intervention.
 ► Feasibility study, so limited to data from 2015 only 
and excluding phase I healthy volunteer studies.
 ► Aligning the questions from the XML document was 
not straightforward.
 ► The search terms chosen for the free-text fields 
were not exhaustive and because it was unfeasible 
in a pilot to review all applications, the sensitivity 
and specificity of the text-mining methodology could 
not be calculated.
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Clinical Trials Registry Portal9 provides access to 15 
different regional or national registries, but both have 
markedly less detail than in the study’s research protocol. 
Published evaluations of the literature are likely affected 
by publication bias and there are often discrepancies 
between research publications and their underpinning 
protocols.10
The ability to analyse a large database of application 
forms, each of which contain very detailed information 
taken directly from the research protocol, would enable 
researchers to perform a detailed examination of the 
characteristics of clinical studies, particularly those neces-
sary for generating reliable evidence. This would aid 
understanding of how study characteristics change over 
time and across therapeutic areas, as well as the progress 
of initiatives to improve the quality and relevance of clin-
ical studies.11–15 Therefore, we approached the UK Health 
Research Authority (HRA), which oversees national 
ethical review of health research conducted within the 
National Health Service (NHS). With the support of the 
HRA and having signed the appropriate confidentiality 
declarations, we developed a pilot project to determine 
the feasibility of interrogating with minimal manual inter-
vention the data contained in HARP (HRA Assessment 
Review Portal). HARP is a web-based management infor-
mation system used by the HRA for all research ethics 
applications that require NHS REC (National Health 
Service Research Ethics Committee) review and/or HRA 
approval. We negotiated access to data on clinical studies 
submitted in 2015. The extract had personal data and 
organisational identifiers removed by HRA and did not 
include phase I healthy volunteer studies.
Our pilot focused on automatically summarising the 
characteristics of clinical studies, including therapeutic 
area, blinding, randomisation, use of Independent Data 
Monitoring Committee (IDMC), patient and public 
involvement (PPI) in the research, dissemination of the 
study results and use of new methodologies such as adap-
tive designs.
MethODs
The HRA collects applications for REC ‘approval’ (a 
favourable opinion) through the Integrated Research 
Application System (IRAS)16 and stores them in HARP. 
IRAS is a web-based system used to capture the informa-
tion required by review bodies in the UK, including the 
Medicines and Healthcare Products Regulatory Agency 
and HRA. When the forms are completed, IRAS saves the 
results as an XML document. XML is a commonly used 
file format that stores structured data in plain text. The 
XML document can be used to generate PDF copies of 
the required forms and to repopulate the online web tool 
so users can later edit their applications.
Once the appropriate permissions were agreed, the 
HRA provided us with anonymised applications for 
clinical studies submitted for review from 2014 to 2016, 
excluding phase I healthy volunteer studies. For this 
pilot, we wished to focus on the extraction of clinical 
study characteristics of interest from the PDF versions of 
the HRA forms underlying the IRAS application system. 
We were provided with an incomplete mapping between 
the questions on the PDF and the data stored in the XML 
document, such that many questions relevant to our study 
were not immediately labelled; nor was it apparent which 
questions were effectively switched on and off for appli-
cants in completing the system’s initial filter questions for 
their application. Therefore, we reverse-engineered the 
structure of the data in IRAS to determine which XML 
tags were responsible for creating the content we wanted 
to extract from the XML files to study.
The IRAS tool has been updated over time; not all 
of applications were created using the same version. 
Although the majority (91%) of the XML documents 
were created with one version (the latest version of the 
tool in the dataset), eight different versions were present 
in the dataset we received. We were not provided with the 
documentation detailing the ways in which the versions 
differed; we had access only to the latest version. Our 
inspection of the data indicated that the differences 
relevant to this pilot study were minor and we corrected 
for these when they were detected; however, there may 
be some undetected differences where the distinction 
between versions was important for our study.
For our pilot project, we chose to collect information 
on: the number of randomised controlled trials (RCT); 
the trial phase; the therapeutic area; the number of clin-
ical trials of investigational medicinal products (CTIMPs 
— trials that require registration with regulatory body); 
the research method used (eg, RCT, feasibility/pilot study, 
blinding); the use of blinding; the use of systematic or 
formal literature reviews in planning the study; the use of 
adaptive or Bayesian designs; the use of a data monitoring 
committee; the plans for dissemination of findings; and 
the role of PPI in aspects of the research. Success would 
be measured in terms of our ability to access the infor-
mation and generate descriptive summaries with minimal 
need for manual data reviews.
The data for our target areas were either held in 
multiple choice questions that we could identify and 
summarise or in free-text fields from which information 
needed to be determined and extracted. For those ques-
tions, we preprocessed the text using Spacy (https:// 
spacy. io/), a natural language processing (NLP) package 
for Python. This involved identifying sentence bound-
aries and performing morphological analysis to convert 
words into their canonical dictionary form. We then used 
regular expressions to match phrases we were interested 
in, ignoring differences relating to spacing, hyphenation 
and capitalisation; Roman numerals were standardised to 
Latin numbers. For example, when looking for evidence 
that a systematic review was either performed or an 
existing review used during the study planning process, we 
searched for phrases such as ‘systematic review’, ‘reviewed 
systematically’, ‘literature review’, ‘evidence review’ 
and ‘evidence-based review’ in the answers provided to 
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Table 1 Overview of research activities submitted for REC approval
Characteristic
RCT Other Total
N % N % N %
N 963 812 1775
Therapeutic area*
  Cancer 168 17 192 24 360 20
  Cardiovascular 94 10 94 12 188 11
  Musculoskeletal 97 10 30 4 162 9
  Respiratory 97 10 30 4 159 9
  Paediatrics 56 6 30 4 148 8
  Neurological 73 8 30 4 145 8
  Mental health 66 7 30 4 117 7
  Inflammatory and immune system 72 7 30 4 113 6
  Oral and gastrointestinal 64 7 30 4 113 6
  Blood 44 5 67 8 111 6
  Diabetes 58 6 38 5 96 5
  Infection 55 6 30 4 92 5
  Renal and urogenital 39 4 30 4 82 5
  Generic health relevance 46 5 30 4 76 4
  Metabolic and endocrine 32 3 30 4 70 4
  Dementias and neurodegenerative 27 3 36 4 63 4
  Skin 36 4 30 4 57 3
  Reproductive health and childbirth 30 3 30 4 56 3
  Stroke 27 3 30 4 53 3
  Eye 24 2 28 3 52 3
  Injuries and accidents 22 2 30 4 36 2
  Congenital disorders 10 1 20 2 30 2
  Ear 6 1 7 1 13 1
Count of therapeutic areas claimed
  None 52 5 49 6 101 6
  1 660 69 495 61 1155 65
  2 201 21 200 25 401 23
  3 29 3 49 6 78 4
  ≥4 21 2 19 2 40 2
Research methods used*
  RCT 963 100 2 0 965 54
  Feasibility/pilot study 177 18 300 37 477 27
  Questionnaire 98 10 139 17 237 13
  Cohort observation 23 2 161 20 184 10
  Qualitative research 90 9 76 9 166 9
  Controlled trial, no randomisation 3 0 157 19 160 9
  Laboratory study 30 3 47 6 77 4
  Case series/case note review 7 1 45 6 52 3
  Cross-sectional study 4 0 31 4 35 2
  Case–control study 5 1 25 3 30 2
  Database analysis 8 1 17 2 25 1
  Epidemiology 7 1 5 1 12 1
Continued
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the relevant questions on the form, or instances where 
these words were used near each other, where ‘near’ 
was defined as being within three words. For adaptive 
designs, we employed the US Food and Drug Adminis-
tration (FDA) definition, namely ‘a study that includes 
a prospectively planned opportunity for modification’.17 
We extracted the sentence containing the target phrase 
as well as one sentence before and after into a separate 
document. These textural extracts were then reviewed by 
the authors to identify true and false positives.
The data extracted from the separate XML files were 
collated into one dataset and descriptive analyses of this 
dataset were done with Stata.
results
We received (30 June 2016) the XML files for 1814 appli-
cation records submitted for ethical review during the 
period specified, and extracted by HRA from the IRAS 
system. Of these, 1659 (92%) were from 2015, 154 (9%) 
from 2014 and 1 was from 2016. Three records were 
corrupted and could not be processed. In discussion with 
HRA, we discarded some records to remove duplicates. 
We kept one of four entries for the WHEAT trial which 
had been sent to multiple committees as part of research 
on consistency of REC opinions.18 We discarded one of 
two entries for a further study, which was initially given 
a favourable opinion and then submitted additionally to 
a specialist REC in Scotland (again, favourably). Thir-
ty-two further records were discarded that initially had an 
unfavourable opinion before re-submission as a (near) 
identical, separate application for review. We discarded 
the first applications and kept the re-submissions, regard-
less of the subsequent review’s outcome. Therefore, our 
dataset included 1775 studies.
The filter questions switched off, for some applications, 
questions in which we were interested. For example, 
trial phase was only recorded for CTIMPs and the use of 
data monitoring committees was infrequently recorded. 
Furthermore, the use of blinding was not sufficiently well 
captured in the system to allow us to present reliable data.
Characteristic
RCT Other Total
N % N % N %
  Meta-analysis 0 0 0 0 0 0
  Other 68 7 269 33 337 19
Count of research methods used
  1 641 67% 522 64 1163 66
  2 192 20 160 20 352 20
  3 73 8 97 12 170 10
  4 48 5 25 3 73 4
  5 7 1 7 1 14 1
  6 2 0 1 0 3 0
CTIMP
  Unlicensed 315 33 189 23 504 28
  New use 146 15 70 9 216 12
  Within SmPC 66 7 26 3 92 5
  Other 10 1 5 1 15 1
  Any of these 515 53 284 35
Involves ionising radiation
  Yes 666 69 582 72 1248 71
  No 297 31 222 28 519 29
  Missing 0 NA 8 NA 8 NA
REC opinion
  Favourable 942 98 798 98 1740 98
   Favourable 200 21 217 27 417 23
   Favourable (extra info) 742 77 581 72 1323 75
  Unfavourable 21 2 14 2 35 2
*Not mutually exclusive.
CTIMP, clinical trials of investigational medicinal product; RCT, randomised controlled trial; REC, Research Ethics Committee; 
SmPC, summary of product characteristics.
Table 1 Continued 
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A total of 963/1775 (54%) of the applications were 
stated as being RCTs. Table 1 describes the disease setting, 
research method, CTIMP and REC opinion by whether 
they were an RCT. The most common research area, 
using the categorisation of the IRAS system, was cancer, 
followed by cardiovascular, musculoskeletal and respira-
tory diseases; around one-third of records specified more 
than one area. This is broadly consistent with previous 
reviews.19 20 Around one-fifth of RCTs were pilot studies; 
one-third of records were employing more than one 
method. The REC gave a favourable opinion to the vast 
majority of applications (1740/1775, 98%), but required 
additional information for most of these 1323/1740 
(75%).
Over half of the RCTs (515/963, 53%) were CTIMPs, of 
which 315/515 (61%) were CTIMPs of unlicensed prod-
ucts, 146/515 (28%) licensed CTIMPs in a new setting 
and 66/515 (13%) CTIMPs used according to their 
summary of product characteristics (SmPC); the catego-
ries were not mutually exclusive. Over a third (284/812, 
35%) of the other studies (not RCTs) were also CTIMPs.
Table 2 describes the plans in design and dissemina-
tion. Most RCTs (895/963, 93%) were not recorded as 
being preceded by a formal systematic review of the litera-
ture. Only 15 (2%) RCTs were detectably designed under 
a Bayesian framework; 20 (2%) were detectable as having 
an adaptive design. There were 34 cluster randomised 
and 5 stepped wedge trials, overall. Six hundred fourteen 
(63%) RCTs were requesting new biological samples; 120 
(12%) RCTs were seeking access to previous biological 
samples.
The large majority of research (1667/1775, 94%) was 
planned for dissemination in the peer-reviewed literature 
and most (1585/1775, 89%) were planned for confer-
ence presentations. A total of 475/963 (49%) RCTs and 
352/812 (43%) other studies were planned for submission 
Table 2 Issues in design and dissemination in all entries
Characteristic
RCT Other Total
N % N % N %
N 963 812 1775
Review of data as part of development
  Neither 895 93 759 93 1654 93
  Systematic review only 38 4 32 4 70 4
  Meta-analysis only 18 2 13 2 31 2
  Both 12 1 8 1 20 1
Design characteristics
  Neither 926 96 778 96 1704 1
  Adaptive design 20 2 9 1 29 2
  Bayes design 15 2 24 3 39 2
  Both 2 0 1 0 3 0
  Cluster randomised 26 3 8 1 34 2
  Stepped wedge 3 0 2 0 5 0
Sample collection*
  Taking new samples 614 64 422 52 1036 58
  Accessing stored samples 120 12 110 14 230 13
Plans for dissemination†
  Peer-reviewed scientific journal 912 95 755 93 1667 94
  Conference presentation 869 90 716 8 1585 89
  Internal report 641 67 526 65 1167 66
  Publication on website 536 56 367 45 903 51
  Submission to regulatory authority 475 49 352 43 827 47
  Other publication 239 25 178 22 417 23
  Access to raw data 191 20 133 16 114 6
  Other 0 0 3 0 324 18
  No plans to report or disseminate 3 0
*Not asked for non-regulatory RCTs.
†Not mutually exclusive.
RCT, randomised controlled trial.
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to regulatory authorities. A small number, 114/1775 
(6%), were planning to offer raw data to external appli-
cants as a key form of dissemination.
Table 3 notes the reported patients and public involve-
ment (PPI) using the categories specified by IRAS. A total 
of 726/1775 (41%) of studies claim PPI in the design 
and 659/1775 (37%) claim planned PPI in dissemina-
tion of the findings. PPI engagement in undertaking and 
management of the research was less common, and few 
studies (147/1775, 8%) involved planned PPI in analysis. 
Around one-third of studies involve PPI in two or more of 
these IRAS-defined areas.
Table 4 shows within CTIMPs the similarities and 
differences across the phase of research. Trial phase was 
asked as a series of separate yes/no questions for phase 
I, II, III and IV. These were not mutually exclusive. For 
the purpose of summarising, we selected the highest 
level if more than one option was selected. Early phase 
trials were more likely to be designed within a Bayesian 
framework; phase III trials most often reported the use 
of a placebo and the use of an Independent Data Moni-
toring Committee; phase IV trials were least likely to be 
submitted to a regulatory authority or put on a website, 
but most often reported PPI in all five broad areas.
Table 5 shows the outcome of the manual review of the 
extracted free-text fields. Accuracy, defined as number 
of true positives divided by overall total ranged from 
43% for adaptive designs to 100% for stepped wedge. 
The false positives related to studies described as ‘phase 
1/2’ or ‘phase 2/3’, but with no evidence of an adaptive 
step, for example, phase 1/2 was often used to describe 
a classical pharmacokinetic study in patients rather than 
healthy volunteers; the database did not contain healthy 
volunteer studies. For ‘systematic review’ and ‘meta-anal-
ysis’, the search often picked up references to previous 
studies and not the planned study.
DIsCussIOn
We achieved our primary feasibility aim of negotiating 
access to the centralised UK approvals system and devising 
a way of extracting information from a series of separate 
XML files. We anticipate that the programmes we devel-
oped could extract further pertinent points of informa-
tion with minimal manual involvement. We were also able 
to achieve our primary descriptive aim of systematically 
reporting on the state of clinical research in the UK over 
around 1 year, focused on 2015.
We found that nearly 1000 RCTs were submitted for 
approval in the UK during that period and >800 other 
studies. A key message is the volume of research activity 
in the UK, with the country demonstrably research 
active. The majority of applications received a favour-
able opinion but most required further information first, 
suggesting that applications could be better completed, 
saving time and effort for all parties.
It was notable that the reported use of adaptive designs 
was low and was not markedly different from earlier esti-
mates.19 20 This is disappointing, as many members of this 
design family have scope to reduce time to answer and/
or reduce the average cost per answer, particularly by 
moving away early from treatment approaches that are 
not likely to improve outcomes sufficiently for patients.21 
However, Bayesian approaches have penetrated 10% of 
early phase CTIMPs. The reported use of IDMCs for 
phase III CTIMPs was, perhaps, low at 58%, but this 
Table 3 Reported PPI
Characteristic
RCT Other Total
N % N % N %
N 963 812 1775
Areas of PPI activity*
  Design of the research 403 42 323 40 726 41
  Dissemination of findings 375 39 284 35 659 37
  Undertaking the research 242 25 219 27 461 26
  Management of the research 225 23 129 16 354 20
  Analysis of results 72 7 75 9 147 8
Number of areas of PPI activity
  None 389 40 302 37 691 39
  1 205 21 209 26 414 23
  2 139 14 117 14 256 14
  3 125 13 93 11 218 12
  4 66 7 37 5 103 6
  All 39 4 32 4 71 4
*Not mutually exclusive.
PPI, patient and public involvement.
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is a substantial increase over the prevalence in trials 
published in high impact-factor journals in 1990 and 
2000.22 Involvement of patients and the public in various 
aspects of research is increasingly seen as important, 
but reported rates of engagement were quite low: more 
than half of studies had no PPI involvement.23 Cursory 
review of the free-text fields associated with these PPI 
categories suggests that some applicants may have been 
a little generous in choosing to select a particular cate-
gory, suggesting that the numbers we report may be 
overestimates. Other comments suggest that PPI is not 
needed, perhaps reflecting that the value of PPI is yet to 
Table 4 Characteristics of the CTIMPs by trial phase
Trial phase* Ph I Ph II Ph III Ph IV Total
Characteristic N % N % N % N % N %
All entries, N 99 287 324 98 808
Design characteristics
  Neither 86 89 261 93 303 94 90 94 740 93
  Adaptive 1 1 7 2 13 4 3 3 24 3
  Bayes 10 10 12 4 5 2 2 2 29 4
  Both 0 0 2 1 0 0 1 1 3 0
  Cluster randomised 0 0 0 0 0 0 0 0 0 0
  Stepped wedge 0 0 0 0 0 0 0 0 0 0
  Involves placebo 21 22 123 44 163 51 25 26 332 42
Independent data monitoring committee
  No 40 82 84 59 61 42 46 78 231 58
  Yes 9 18 59 41 84 58 13 22 165 42
  Missing 8 139 176 37 400
Methods of dissemination
  Peer-reviewed scientific journal 86 89 265 94 290 90 93 97 86 89
  Submission to regulatory 
authority
85 88 215 76 272 85 48 50 85 88
  Conference presentation 82 85 253 90 271 84 89 93 82 85
  Internal report 71 73 212 75 259 81 60 63 71 73
  Publication on website 56 58 161 57 203 63 45 47 56 58
  Other publication 26 27 76 27 92 29 17 18 26 27
  Access to raw data 8 8 12 4 25 8 8 8 8 8
  Other 12 12 47 17 48 15 18 19 12 12
  No plans to report or 
dissemination
0 0 0 0 2 1 0 0 0 0
Areas of PPI activity†
  Design of the research 26 27 82 29 39 12 50 52 26 27
  Management of the research 10 10 34 12 28 9 31 32 10 10
  Undertaking the research 14 14 47 17 36 11 29 30 14 14
  Analysis of results 1 1 15 5 7 2 12 13 1 1
  Dissemination of findings 20 21 74 26 64 20 44 46 20 21
  None of the above 53 55 149 53 223 69 35 36 460 58
REC opinion
  Favourable 97 98 277 97 318 98 93 95 785 97
   Favourable 14 14 51 18 40 12 15 15 120 15
   Favourable (after extra info) 83 84 226 79 278 86 78 80 665 82
  Unfavourable 0 0 5 2 3 1 3 3 11 1
*Trial phase calculated.
†Not mutually exclusive.
CTIMP, clinical trials of investigational medicinal product; PPI, patient and public involvement; REC, Research Ethics Committee.
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Table 5 Review of possible search terms
Design element
Search term
Performance of search term*
At sentence level At study level
True positive False positive Accuracy True positive False positive Accuracy
Systematic review
  Review (near) systematically 2 0 100 2 0 100
  Evidence (near) review 4 1 80 4 1 80
  Systematic (near) review 98 39 72 58 23 72
  Literature (near) review 29 13 69 26 12 68
  Evidence-based review 0 0 NA 0 0 NA
  Summary*† 133 53 72 90 36 71
Meta-analysis
  Pooled analysis 2 0 100 2 0 100
  Meta-analysis 77 31 71 49 19 72
  Integrated analysis 0 0 NA 0 0 NA
  Summary*† 79 31 72 51 19 73
Adaptive design
  Adaptive design 19 0 100 13 0 100
  Adaptive randomisation 8 0 100 5 0 100
  Continual reassessment 2 0 100 1 0 100
  Sample size re-estimation 15 0 100 9 0 100
  Seamless design 1 0 100 1 0 100
  Phase I/II 4 43 9 3 37 8
  Phase II/III 2 25 7 2 23 8
  CRM design 0 0 NA 0 0 NA
  Drop-the-loser 0 0 NA 0 0 NA
  MAMS design 0 0 NA 0 0 NA
  Multiarm multistage 0 0 NA 0 0 NA
  Pick-the-winner 0 0 NA 0 0 NA
  Summary*† 51 68 43 31 60 34
Bayes
  Bayes 83 2 98 42 1 98
  Summary*† 83 2 98 42 1 98
Cluster RCT
  Cluster RCT 26 0 100 11 0 100
  Control cluster 6 0 100 4 0 100
  Randomised cluster 2 0 100 1 0 100
  Cluster random 46 1 98 30 1 97
  Summary*† 80 1 99 34 1 97
Stepped wedge
  Step (near) wedge 1 0 100 1 0 100
  Stepped (near) wedge 16 0 100 5 0 100
  Summary*† 17 0 100 5 0 100
NB The table reports on whether each search term accurately identified a specific design element of the study in selected free-text fields. All variations 
of the spelling, capitalisation, hyphenation and so on were covered in the search terms used.
*The left side of the table separately considers each sentence which matched a search term accurately identified the design property. There were 613 
such sentences. The Summary row in each subsection is the sum of the constituent search terms.
†The right side of the table separately considers whether any sentence in a study matching a search term accurately identified the design property. 
Some studies matched a search term repeatedly, therefore the numbers are smaller. The Summary row in each subsection reflects a search across all 
of its constituent search terms. Note that some studies matched more than one search term in a subsection, so the Summary row may not be the sum 
of the rows above for example, a study that uses both ‘cluster random’ and ‘control cluster’ would appear only once in the Summary row, and would 
appear separately in the ‘cluster random’ and ‘control cluster’ rows.
CRM,  continual reassessment method; MAMS, multi-arm multi-stage; RCT, randomised controlled trial.
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be recognised by some researchers.3 Further research in 
this area is required.
Most but not all studies were planned for publication; 
there is still some way to go on this transparency aim. 
That raw data would be made available for some studies is 
encouraging and we hope that this will increase with time 
for appropriate projects from qualified researchers.24
Extracting the information from the HRA system was 
more effortful than expected. Moreover, important 
characteristics of clinical trials like blinding could not 
be analysed and certain search terms clearly had limita-
tions. The issue of blinding is particularly important, as 
it is one of the desirable characteristics in generating 
reliable evidence from clinical trials.11 However, now that 
we have completed this feasibility step, it is possible for 
future research projects to access an expanded dataset 
and work with the HRA to organise the database in a way 
that will facilitate its analysis. Access to several years of 
data would allow researchers, as well as the HRA itself, to 
examine the progress of initiatives to improve the quality 
of clinical research, such as those designed to encourage 
PPI and publication of clinical trial results.13 15 We would 
also encourage the HRA to adopt standard definitions 
to describe the characteristics of clinical trials, as done 
in the USA.25 Confusion over the definition of terms 
greatly complicates efforts to automatically analyse clin-
ical research.
Our pilot work has some limitations. We had no 
straightforward way of aligning the questions in the PDF 
document with the information stored in the XML docu-
ment. Perhaps if we had negotiated access to the backend 
software used by IRAS to generate these PDF forms, we 
may have been able to do this automatically; instead, we 
needed to reverse-engineer the IRAS system in order to 
figure out which XML tags were responsible for creating 
the content we wanted to study. Not all of the applica-
tions had been created using the same version of the 
IRAS tool.16 Although a large majority of the documents 
were created using the latest version of the tool, eight 
different versions were present in the dataset we received. 
We did not receive any guidance on the ways in which one 
version of the tool differed from another version, and we 
only had access to the latest version. We made efforts to 
determine the specific situations in which questions were 
not asked rather than asked but not answered, in order to 
make this distinction ourselves, though ideally this could 
be indicated directly in the XML dataset. The labelling of 
missing answers and inactivated questions was not consis-
tent. There is scope for applicants to misunderstand 
the questions and misrepresent the data. For example, 
three trials were noted as using RCT methodology but 
answered ‘no’ to the question: ‘Will participants be allo-
cated to groups at random?’ We checked the data and 
found these were not actually RCTs; we included them 
with the ‘other studies’. Likely this error by the applicants 
activated or de-activated some questions inappropri-
ately. In this example, the RCT method question actually 
asked about randomisation of individuals and these three 
applicants who submitted cluster randomised trials had 
answered this question inconsistently. Finally, the search 
terms chosen for the free-text fields were not exhaus-
tive and because it was unfeasible in a pilot to review all 
applications, the sensitivity and specificity of the free-text 
extraction could not be calculated.
Some interesting information was held only in the 
free-text fields. We used standard methods to extract 
this information using automation supplemented by 
manual checking. There is a wealth of free-text informa-
tion, which through the application of text-mining tech-
niques could provide incredibly valuable insights into the 
characteristics of health research. For this pilot study, we 
did not have the resources to review all of the questions 
and we particularly could not spend time reading free-
text fields. Therefore, we felt obliged not to correct cate-
gorical questions if we noticed they were contrasted by 
free-text; however, a fully-resourced study could do this. 
For example, we noticed at least one entry, which ticked 
boxes for PPI engagement and expanded on this by 
claiming that, as doctors, they knew what patients wanted 
and did not need to trouble patients for their time on 
these aspects.
In conclusion, we have demonstrated that anonymised 
data from the HRA’s research system are accessible and 
can be queried for information. We strongly encourage 
the development of fully resourced collaborative projects 
to delve more deeply into this data. We believe that it is 
imperative that the characteristics of clinical research 
in the UK are understood, as these underpin clinical 
guidance. Finally, there are many ongoing initiatives to 
improve the quality of clinical research, but only by fully 
understanding the state of, and changes to, the research 
profile of the UK, can we appreciate their impact.
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